NCT04427995 (OMNIgl) is a clinical trial of OMNI surgical system in Open Angle Glaucoma, sponsored by Iqbal Ahmed.

Who is sponsoring NCT04427995?

NCT04427995 is sponsored by Iqbal Ahmed.

What drugs are being tested in NCT04427995?

Interventions in NCT04427995: OMNI surgical system.

What condition does NCT04427995 study?

NCT04427995 studies Open Angle Glaucoma.

Is NCT04427995 still recruiting?

NCT04427995 is currently terminated. Last updated 26 July 2021.

Last reviewed 2021-07-26 · How we verify

NCT04427995: OMNIgl

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standalone OMNI Surgical System for Open-angle Glaucoma

Terminated Last updated 26 July 2021

What this trial tests

trial testing OMNI surgical system in Open Angle Glaucoma in 30 participants. Terminated before completion.

Timeline

25 March 2019

Primary endpoint
31 March 2021

1 April 2021

Quick facts

Lead sponsor	Iqbal Ahmed
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	30
Start date	25 March 2019
Primary completion	31 March 2021
Estimated completion	1 April 2021
Sites	1 location across Canada

Drugs / interventions tested

OMNI surgical system

Conditions studied

Open Angle Glaucoma — all drugs for Open Angle Glaucoma →

Sponsor

Iqbal Ahmed

Who can join

Adults 30 to 95, any sex, with Open Angle Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The emergence of minimally invasive glaucoma surgeries (MIGS) has seen a variety of potential innovative surgical alternatives to help better control intraocular pressure (IOP). The OMNI™ Surgical System (Sight Sciences, Menlo Park, CA, USA) is a promising MIGS procedure. It combines two procedures known as trabeculotomy and viscodilation of Schlemm's canal in one hand held device without the need for additional incisions or extra instrumentation. The device recently received FDA approval in the United States for certain indications in ophthalmic surgery. To date, no study has examined the effect of standalone viscodilation and trabeculotomy on glaucoma drop burden and IOP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

NCT07228221 — Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma · Phase 4 · recruiting
NCT06883123 — Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · Phase 4 · recruiting
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT06246136 — Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery · NA · recruiting
NCT06061718 — Travoprost Intraocular Implant in Conjunction With Cataract Surgery · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04427995 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Iqbal Ahmed
Last refreshed: 26 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04427995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing